Cellectar Total Current Assets from 2010 to 2026
| CLRB Stock | USD 3.29 0.15 4.78% |
Total Current Assets | First Reported 2005-03-31 | Previous Quarter 12.6 M | Current Value 13.6 M | Quarterly Volatility 12 M |
Check Cellectar Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectar Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 289 K, Interest Expense of 363.4 K or Total Revenue of 0.0, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.72 or Days Sales Outstanding of 741. Cellectar financial statements analysis is a perfect complement when working with Cellectar Biosciences Valuation or Volatility modules.
Cellectar | Total Current Assets | Build AI portfolio with Cellectar Stock |
Analyzing Cellectar Biosciences's Total Current Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Current Assets has evolved provides context for assessing Cellectar Biosciences's current valuation and future prospects.
Latest Cellectar Biosciences' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Cellectar Biosciences over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Cellectar Biosciences' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectar Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Cellectar Total Current Assets Regression Statistics
| Arithmetic Mean | 16,624,383 | |
| Geometric Mean | 9,729,574 | |
| Coefficient Of Variation | 89.12 | |
| Mean Deviation | 11,378,219 | |
| Median | 11,385,673 | |
| Standard Deviation | 14,815,951 | |
| Sample Variance | 219.5T | |
| Range | 57.8M | |
| R-Value | 0.65 | |
| Mean Square Error | 136.3T | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 1,897,030 | |
| Total Sum of Squares | 3512.2T |
Cellectar Total Current Assets History
About Cellectar Biosciences Financial Statements
Cellectar Biosciences stakeholders use historical fundamental indicators, such as Cellectar Biosciences' Total Current Assets, to determine how well the company is positioned to perform in the future. Although Cellectar Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectar Biosciences' assets and liabilities are reflected in the revenues and expenses on Cellectar Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectar Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 27.9 M | 29.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out the analysis of Cellectar Biosciences Correlation against competitors. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. Projected growth potential of Cellectar fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cellectar Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cellectar Biosciences requires distinguishing between market price and book value, where the latter reflects Cellectar's accounting equity. The concept of intrinsic value - what Cellectar Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cellectar Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Cellectar Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectar Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cellectar Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.